SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Landipirdine (Primary)
- Indications Parkinson's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms SYNAPSE
- Sponsors Biotie Therapies Corp.
- 17 Jan 2018 Status changed from active, no longer recruiting to completed.
- 08 Jan 2018 According to the Acorda Therapeutics media release, company continues to review the data which will be presented at an upcoming medical meeting.
- 01 Aug 2017 Status changed from recruiting to active, no longer recruiting.